Vera Mogna

This inventor holds 4 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignee: Probiotical S.p.a.. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vera Mogna. Retrieved from https://idiyas.com/inventor/vera-mogna

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 3.2

ph-index = 1

Company Filing History:

4 out of 32

Probiotical S.p.a.

patents

Years Active: 2025-2026

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12553023 - Homogenisation process for the preparation of a cellular component homogenate (2026-02-17),

2. 12509713 - Use of a cytofluorometry method for evaluating the stability and viability of a biomass of freeze-dried bacterial cells (2025-12-30),

3. 12472216 - Compositions comprising bacterial strains and use thereof for the treatment of ocular diseases and lesions (2025-11-18),

4. 12329791 - Mixture of probiotic bacteria strains for use in the treatment of allergic asthma and with recurrent wheezing, preferably in paediatric subjects (2025-06-17),

Title: Vera Mogna: Innovator in Probiotic Treatments

Introduction

Vera Mogna is a notable inventor based in Novara, Italy. She has made significant contributions to the field of probiotics, particularly in the treatment of ocular diseases and respiratory ailments. With a total of 4 patents, her work is paving the way for innovative therapeutic solutions.

Latest Patents

Mogna's latest patents include compositions comprising bacterial strains for the treatment of ocular diseases and lesions. This invention focuses on mixtures that include at least one probiotic bacterial strain, aimed at preventing and curing inflammatory ocular lesions. The second patent involves a mixture of probiotic bacteria strains for treating allergic asthma and recurrent wheezing, especially in pediatric subjects. This patent describes an isolated strain of bacteria (B632) DSM 24706, which can be administered to children suffering from respiratory disorders.

Career Highlights

Vera Mogna is currently associated with Probiotical S.p.a., a company dedicated to the development of probiotic solutions. Her work has been instrumental in advancing the understanding and application of probiotics in medical treatments.

Collaborations

Mogna collaborates with notable colleagues, including Marco Pane and Angela Amoruso, who contribute to her research and development efforts.

Conclusion

Vera Mogna's innovative work in probiotics is making a significant impact on the treatment of ocular and respiratory conditions. Her patents reflect a commitment to improving health outcomes through scientific advancements.

Profile summary based on public USPTO records.